Sarcopenia refers to age-related loss of muscle mass and strength. As the elderly population grows worldwide, the prevalence of sarcopenia and associated functional impairments are also increasing. Drugs that increase muscle protein synthesis and decrease protein breakdown have the potential to slow or reverse sarcopenia. Several pharmaceutical companies are conducting clinical trials for potential sarcopenia treatments focusing on muscle anabolism and anti-catabolism.
The global Sarcopenia Treatment Market is estimated to be valued at US$ 3.47 Bn in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The opportunity for drug development in sarcopenia treatment presents a significant market opportunity. Currently, prescription medications for sarcopenia are lacking, with exercise and nutrition changes comprising the major therapeutic interventions. However, the aging population demands more effective pharmacological treatments. Emerging research into potential anabolic and anti-catabolic drug targets provides a solid foundation for innovation. Developers who successfully commercialize drugs reversing muscle loss and functional decline stand to gain first-mover advantage in this emerging market.
Porter's Analysis
Threat of new entrants: Low barriers to entry prevent major threat. However, high R&D required to develop new drugs acts as deterrent.
Bargaining power of buyers: Large customer base of elderly patients gives buyers moderate bargaining power. Customers can choose between available treatment options.
Bargaining power of suppliers: Established drug makers hold strong position due to proprietary drugs and expertise in therapeutic area. Suppliers face minimal threat from substitutes.
Threat of new substitutes: Low threat as sarcopenia has limited treatment alternatives currently. Rising awareness may increase demand for alternative therapies like nutrition and exercise programs.
Competitive rivalry: Intense competition exists between major pharmaceutical firms to gain higher market share through novel drug launches and portfolio expansion.
SWOT Analysis
Strengths: Growing elderly population drives large potential patient pool. Increasing prevalence of sarcopenia opens up opportunities.
Weaknesses: Limited approved treatment options exists currently. High costs involved in drug development acts as a bottleneck.
Opportunities: Scope for nutrition/lifestyle-based intervention programs. Emerging economies with large geriatric population sets scope.
Threats: Stringent regulatory approvals add to risks. Patent expiries of blockbuster drugs increases competition.
Key Takeaways
The Global Sarcopenia Treatment Market Demand is expected to witness high growth over the forecast period owing to the rising geriatric population globally which is more prone to sarcopenia.
Regional analysis suggests that the Asia Pacific region is expected to be the fastest growing market for sarcopenia treatment during the forecast period. This is majorly attributed to factors such as the presence of emerging economies like China and India which have a huge geriatric population base coupled with improving healthcare infrastructure and increasing healthcare spending in the region.
Key players operating in the sarcopenia treatment market are Abbott Laboratories, Sanofi S.A., GlaxoSmithKline plc, Amway, Bayer AG, Pfizer Inc., Novartis AG.
Explore more information on this topic, Please visit -
https://www.ukwebwire.com/sarcopenia-treatment-market-growth-and-forecasts-analysis/
Explore more trending article related this topic -
https://www.pressreleasebulletin.com/cancer-biomarkers-market-growth-and-forecasts-analysis/
